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MATERIALS AND METHODS 
Mixtures of carbamazepine with indomethacin, olanzapine, L-arginine, L-tryptophan, L-proline, citric acid, oxalic acid, tartaric acid and saccharin 
were produced in a 1:1 molar ratio. The molten pairs of substances were quenched cooled with liquid nitrogen to produce the co-amorphous, 
which were characterized by near infrared spectroscopy (NIR, ABB TLA 2000) to identify possible interactions between the compounds and 
differential scanning calorimetry (DSC, TA Instruments QA200) to assess the formation of amorphous or other polymorphic forms of 
carbamazepine.  
RESULTS AND DISCUSSION 
INTRODUCTION 
Bioavailability is a milestone in drug development, since it reflects the amount of drug absorbed that reaches the 
site of action. About 70-90% of all drugs in R&D have problems regarding solubility in water, thus presenting low 
bioavailability (1). Consequently, high doses of drug should be present in the final dosage form to assure therapeutic 
effect (1), resulting in higher costs for both industry and patients. Co-amorphization is a common strategy to 
increase the solubility of drugs in water. The co-amorphous systems can be produced with a mixture of active 
pharmaceutical ingredients (APIs) or a mixture of a drug with one or more small molecular weight excipients (1,2). 
The purpose of this work was the production of co-amorphous entities with carbamazepine, a class II BCS drug, 
nearly insoluble in water (3), and the evaluation of which substances (either APIs or excipients) allowed the 
production of the most stable systems. 
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DRUG-EXCIPIENT AND DRUG-DRUG MIXTURES:  
a pathway for the production of co-amorphous entities 
From DSC analysis it was possible to identify that drug-drug mixtures (carbamazepine-olanzapine and carbamazepine-indomethacin) were 
successfully converted into co-amorphous systems. On the other hand, it was impossible to produce co-amorphous of carbamazepine with any 
of the excipients tested. For the carbamazepine-olanzapine and carbamazepine-indomethacin systems, the NIR spectra showed the 
disappearance of the peak corresponding to the CONH2 functional group of carbamazepine (around 5100 and 6800cm
-1). Furthermore, a 
decrease in the intensity of the NH and OH regions around 5000-4800cm-1 was also found. 
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Fig. 1. Carbamazepine 
molecular structure 
Fig. 2. DSC thermogram obtained for the system 
carbamazepine and olanzapine. 
Fig. 3. NIR spectra obtained for the system 
carbamazepine and olanzapine. 
Fig. 4. Olanzapine molecular 
structure. 
Fig. 5. DSC thermogram obtained for the system 
carbamazepine and indomethacin. 
Fig. 6. NIR spectra obtained for the system 
carbamazepine and indomethacin. 
Fig. 7. Indomethacin molecular 
structure. 
CONCLUSIONS 
Carbamazepine was able to produce co-amorphous mixtures with either of the other drugs (olanzapine or indomethacin), while the blends 
containing carbamazepine and excipients were not converted to the amorphous state. The formation of the co-amorphous system involved the 
formation of hydrogen bonds between the functional groups CONH2 (from carbamazepine) and NH or CO2H, depending on which exist in the 
molecules (olanzapine and indomethacin respectively). The impact of drug:drug co-amorphization on carbamazepine solubility is under 
evaluation. 
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